homocysteine in English
Metabolism of homocysteine requires an adequate supply of folic acid.
Use "homocysteine" in a sentence
1. Betaine serves as a methyl donor in a reaction converting homocysteine to methionine, catalysed by the enzyme Betaine-homocysteine methyltransferase
2. Enhanced plasma levels of homocysteine and ADMA (asymmetric dimethylarginine) contribute to this process.
3. Plasma ADMA, homocysteine, and hsCRP levels were measured in blood samples.
4. Plasma levels of ADMA and homocysteine were determined using high-performance liquid chromatography.
5. 27 Folic acid appears to lower the blood levels of homocysteine, an amino acid.
6. So this particular enzyme converts an amino acid called homocysteine to another amino acid, methionine.
7. Plasma concentrations of homocysteine were analyzed with HPLC and levels of ADMA were measured by ELISA.
8. Elevated levels of homocysteine have also been associated with congenital malformations, miscarriages and low weight of babies at birth.
9. So in this particular -- in this catalytic cycle, we are converting homocysteine to methionine, and that chemistry involves acid base.
10. So the homocysteine is your donor ligand, and you have your metal as the Lewis acid, your acceptor.
11. The transsulfuration pathway is a metabolic pathway involving the interconversion of cysteine and homocysteine, through the intermediate cystathionine.
12. RESULTS: No significant difference in either mean ADMA or homocysteine plasma levels was found between patients and control subjects.
13. Plasma ADMA and homocysteine levels of the occult CAD group were significantly higher than those of the NCA group.
14. CONCLUSIONS: The present study suggests that plasma levels of ADMA and homocysteine are not associated with increased risk for POAG.
15. Intracellular thiols such as glutathione(GSH), cysteine(Cys), and homocysteine(Hcy) play a crucial role in maintaining biological redox homeostasis.
16. On this basis, we investigated the cardiovascular risk factors homocysteine and ADMA in relation to vitamins B6, B12 and folate in elderly people.
17. Moreover, homocysteine was significantly negatively (p < 0.01) related to vitamins B6, B12 and folate, and significantly positively (p < 0.01) correlated to ADMA.
18. Asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, leads to decreased NO bio-availability, while homocysteine has been associated with increased ADMA plasma levels.
19. These Coenzymes are required in the enzymes which change homocysteine to methionine, an amino acid, and in the oxidation of amino acids and fatty acids
20. Betaine is used to reduce homocysteine levels in people with a genetic condition called homocystinuria, in which the amino acid builds up in the body
21. High homocysteine levels are a risk factor for blood Clots in the veins (DVT, PE) or arteries (heart attack, stroke), and hardening of the arteries (atherosclerosis)
22. Preclinical data demonstrated that Agle-177, which is designed to lower abnormally high blood levels of homocysteine, improved important disease-related abnormalities and survival in a mouse model of Homocystinuria
23. A cell-based quantitative assay system for Hcy has been developed by utilizing two Escherichia coli Auxotrophs that grow in the presence of methionine (Met) and either homocysteine (Hcy) or Met, respectively
24. Homocysteine and antiphospholipid antibodies (APL Ab) appear to be particularly suitable for use in corresponding studies, as these would mean that with vitamin supplementation and/or specific anticoagulant regimens targeted medicamentous treatment options are available.
25. Cysteine is an amino acid that enters the body in two ways: first, through Cysteine-containing foods and second, through a metabolic pathway that converts the amino acid methionine to S-adenosyl methionine, on to homoCysteine which then reacts with serine and forms Cysteine.
26. We hypothesized that soy isoflavones would attenuate the anticipated increase in Androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDLC, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine
27. We hypothesized that soy isoflavones would attenuate the anticipated increase in Androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine